Table 3.
Intravenous (IV) Anakinra Dosing Regimen for Primary Indications.
| Primary indications | Initial dose—mg/kg/dose | Initial IV dosing interval—hours | Initial treatment duration a —days | Total treatment duration—days | Dose range d —mg/kg/dose |
|---|---|---|---|---|---|
| MIS-C associated with COVID-19 infection | 2.3 (2.0-4.0) | 12.0 (12.0-12.0) | 3.5 (2.0-5.0) | 8.0 (5.8-10.8) | 1.0-5.0 |
| HLH | 5.0 (3.1-7.5) | 24.0 (15.0-24.0) | N/A b | 11.0 (6.0-11.8) | 1.3-10.0 |
| SoJIA flares | 3.3 (2.9-3.6) | 15.0 (10.5-19.5) | 4.5 (3.8-5.3) | 6.5 (6.3-6.8) | 2.5-4.0 |
| Possible cytokine storm/hyperinflammatory state c | 2.0 | 12.0 | 2.0 | 2.0 | 2.0 |
Note. Data are presented as median (IQR). COVID-19 = coronavirus disease 19; HLH = hemophagocytic lymphohistiocytosis; MIS-C = multisystem inflammatory syndrome in children; SoJIA = systemic onset juvenile idiopathic arthritis.
a
The initial treatment duration is defined as the duration when IV anakinra was originally ordered as initial dosing regimen.
b
The dose and dosing interval were not changed for the indication of HLH, so the initial treatment duration was not applicable.
c
Only 1 patient had possible cytokine storm/hyperinflammatory state, so the median (IQR) was not calculated.
d
Dose range is defined as the minimum to maximum dose given during the total treatment duration.